Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...2526272829303132333435...5960»
  • ||||||||||  Journal:  Vitamin D metabolism in hypercorticism and acromegaly (Pubmed Central) -  Oct 30, 2021   
    It is now recommended to use standard prophylactic and therapeutic doses of vitamin D for the treatment of these diseases, which may not satisfy the therapeutic goals specific to each disease. This review provides information on normal vitamin D metabolism, as well as literature data on the possible relationship and mutual influence between these endocrinopathies and vitamin D metabolism.
  • ||||||||||  Clinical, Journal:  Selective screening of patients with associated somatic diseases as a method of early detection of acromegaly (Pubmed Central) -  Oct 30, 2021   
     As a result of the study, among the group of 1249 patients (mean age 58±13 years) with the presence of concomitant diseases, 9 newly identified patients with acromegaly were found who were prescribed adequate treatment. The introduction of selective screening technology into the practice of an endocrinologist will improve the effectiveness of diagnostic search for patients with acromegaly, more accurately assess the prevalence of the disease in Russia and the need for specialized medical care.
  • ||||||||||  Journal:  The role of glucose and insulin in the metabolic regulation of growth hormone secretion (Pubmed Central) -  Oct 30, 2021   
    Understanding of the pathophysiological basis of these mechanisms is essential for further research of the role of glucose and insulin in the metabolic regulation of growth hormone secretion. However, the studies in animal models are complicated by interspecific differences in the response of growth hormone to glucose loading, and the only possible available model in healthy people may be the hyperinsulinemic euglycemic clamp.
  • ||||||||||  Signifor LAR (pasireotide long acting release) / Novartis
    Clinical, Journal:  Long-term safety and efficacy of long-acting pasireotide in acromegaly. (Pubmed Central) -  Oct 27, 2021   
    Cadherin-1 and Catenin beta-1 play key roles in the different biological characteristics of the two tumor subtypes. The results support the long-term efficacy and safety of pasireotide LAR for acromegaly and support the potential delayed effect of treatment on IGF-1 normalization.
  • ||||||||||  Journal:  Pituitary adenoma…nomen omen? (Pubmed Central) -  Oct 27, 2021   
    This may be classically obtained only with a close multisciplinary collaboration into a PTCOE. It is proposed that improved definition of "invasive" and "aggressive" neoplasms may represent the most clinically effective development in the clinico-neuroradiological-pathological denomination and classification of pituitary adenomas.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Mycapssa (octreotide) / Amryt
    Journal:  Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation. (Pubmed Central) -  Oct 27, 2021   
    We evaluated the oral octreotide formulation, MYCAPSSA® (Chiasma Pharmaceuticals, Needham, MA, USA)...The oral octreotide dose required to achieve these endpoints was over 200 times that of the 0.1 mg immediate-release subcutaneous injection, a reminder of the difficulty in achieving oral absorption of macromolecules. Many acromegaly patients will prefer a convenient twice-daily oral formulation of octreotide compared to monthly depot injections.
  • ||||||||||  Clinical, Observational data, Journal:  ACROMEGALY IN REMISSION: A VIEW FROM THE PARTNER. (Pubmed Central) -  Oct 27, 2021   
    The quality of life of relatives was not altered and was significantly higher in the social domain than for the patient. Conclusions Our results show that relatives require education concerning all the steps involved in the management of acromegaly, as they likely do not fully understand the sequelae of acromegaly.
  • ||||||||||  temozolomide / Generic mfg.
    Journal:  An aggressive poorly differentiated plurihormonal Pit-1-positive adenoma. (Pubmed Central) -  Oct 25, 2021   
    Temozolomide is first-line chemotherapy for aggressive pituitary tumours and carcinomas. Further development of novel targeted therapies, such as peptide receptor radionuclide therapy (PRRT), vascular endothelial growth factor (VEGF) receptor-targeted therapy, tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and immune checkpoint inhibitors, is needed.
  • ||||||||||  Journal:  Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? (Pubmed Central) -  Oct 22, 2021   
    Further development of novel targeted therapies, such as peptide receptor radionuclide therapy (PRRT), vascular endothelial growth factor (VEGF) receptor-targeted therapy, tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and immune checkpoint inhibitors, is needed. Germline MAX mutations are associated with PCs, ganglioneuromas, neuroblastomas, pituitary neuroendocrine tumors, and, possibly, parathyroid adenomas, as well as non-endocrine tumors of chondrosarcoma and lung adenocarcinoma, suggesting MAX is a novel multiple endocrine neoplasia gene.
  • ||||||||||  Clinical, Journal:  Predictors of postoperative biochemical remission in acromegaly. (Pubmed Central) -  Oct 22, 2021   
    Germline MAX mutations are associated with PCs, ganglioneuromas, neuroblastomas, pituitary neuroendocrine tumors, and, possibly, parathyroid adenomas, as well as non-endocrine tumors of chondrosarcoma and lung adenocarcinoma, suggesting MAX is a novel multiple endocrine neoplasia gene. In this nationwide study spanning over two decades, we highlight that higher preoperative GH levels, large tumor size, and greater extent of tumor invasiveness are associated with a lower likelihood of biochemical remission at 3-months after surgery, while preoperative medical therapy increases the chance of remission.
  • ||||||||||  Journal, HEOR:  Differences in quality of life between genders in acromegaly. (Pubmed Central) -  Oct 22, 2021   
    There is much to be routinely done to improve secondary psychopathology in patients affected by this disease. The need for mental status screening at diagnosis should be emphasized to identify secondary mental illnesses to improve QoL with its treatment.
  • ||||||||||  Journal:  The acromegaly registry of ten different centers in Turkey. (Pubmed Central) -  Oct 14, 2021   
    Transsphenoidal surgery in the treatment of acromegaly still remains the most valid method. Medical treatment options may improve long-term disease outcomes in patients who cannot be controlled with surgical treatment (up to 70%).
  • ||||||||||  Clinical, Journal:  Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients. (Pubmed Central) -  Oct 14, 2021   
    Further follow-up of the patient and cascade screening of her family members should be carried out to determine the clinical significance of the variant p.Val167Ala. GKS is an effective adjuvant treatment with minimal side effects to control GH and IGF-1 levels, increase remission rates, endocrine control, and reduce tumor diameter in persistent acromegaly patients after surgery.
  • ||||||||||  Clinical, Journal:  Health Benefit Costs and Absenteeism Among Employed Patients With Acromegaly. (Pubmed Central) -  Oct 14, 2021   
    GKS is an effective adjuvant treatment with minimal side effects to control GH and IGF-1 levels, increase remission rates, endocrine control, and reduce tumor diameter in persistent acromegaly patients after surgery. The presence of acromegaly was associated with increased direct and indirect employee health benefit costs and increased work absenteeism.
  • ||||||||||  cabergoline / Generic mfg.
    Journal:  The prevalence of silent acromegaly in prolactinomas is very low. (Pubmed Central) -  Oct 13, 2021   
    The prevalence of silent acromegaly in prolactinomas (0.7%) is lower than previously reported and OGTT is helpful to recognize silent acromegaly. We suggest that the somatotroph axis should be evaluated at diagnosis in all cases and not systematically during follow-up.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Review, Journal:  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk? (Pubmed Central) -  Oct 13, 2021   
    Pasireotide is associated with QT prolongation. In the absence of good quality data on risk of arrhythmia in acromegaly, the majority of position statements and guidelines suggest routine 12-lead electrocardiography (ECG) and transthoracic echocardiography (TTE) in every patient at diagnosis and then follow up dependent on initial findings.
  • ||||||||||  Review, Journal:  Dermatological and endocrine elements in Carney complex (Review). (Pubmed Central) -  Oct 12, 2021   
    Two particular mammary tumors are found: myxoid fibroadenomas and breast myxomatosis. Cutaneous/subcutaneous lesions, pigmented or not, or any focal swelling of non-identified cause needs careful examination, since dermatological elements are among the earliest and most discernable by which to detect lesions in CNC, a systemic condition with multi-level endocrine involvement.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Clinical, Review, Journal:  Skin anomalies in acromegalic patients (Review of the practical aspects). (Pubmed Central) -  Oct 12, 2021   
    Iatrogenic rash, lipodystrophy (lipoatrophy with/without lipohypertrophy) are rarely reported after pegvisomant/somatostatin analogues or after insulin use for DM...In non-acromegalic subjects, the exact role of GH/IGF-1 in skin tumorigenesis is yet to be determined. Skin in acromegaly speaks for itself, either as the first step of disease identification or as a complication or part of a complex syndromic context.
  • ||||||||||  Journal:  Acromegaly: achieving timely diagnosis and improving outcomes by personalized care. (Pubmed Central) -  Oct 10, 2021   
    Early diagnosis can be achieved by suspecting acromegaly based on suggestive clinical scenarios rather than obvious changes in appearance. Personalized care entails a proactive multidisciplinary approach to identify and treat comorbidities while carefully monitoring the effects of acromegaly treatment.
  • ||||||||||  Journal:  Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. (Pubmed Central) -  Oct 8, 2021   
    Personalized care entails a proactive multidisciplinary approach to identify and treat comorbidities while carefully monitoring the effects of acromegaly treatment. Radiomic features may be useful biomarkers to differentiate granulation pattern of GH-secreting pituitary adenoma patients, and showed better performance than qualitative assessment or rSI evaluation.